Generation of three induced pluripotent stem cell lines from individuals with Aicardi-Goutières syndrome caused by a c.3019G>A (p.G1007R) autosomal dominant pathogenic variant in ADAR1.

Mutations in Adenosine deaminase acting on RNA 1 (ADAR1) gene encoding RNA editing enzyme ADAR1 results in the neuroinflammatory leukodystrophy Aicardi Goutières Syndrome (AGS). AGS is an early onset leukoencephalopathy with an exacerbated interferon response leading to neurological regression with intellectual disability, spasticity, and motor deficits. We have generated three induced pluripotent stem cell (iPSC) lines from peripheral blood mononuclear cells (PBMCs) of individuals with ADAR1 ^G1007R mutation. The generated iPSCs were investigated to confirm a normal karyotype, pluripotency, and trilineage differentiation potential. The reprogrammed iPSCs will allow us to model AGS, dissect the cellular mechanisms and testing different treatment targets.
Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Adeline Vanderver reports financial support was provided by Commonwealth Universal Research Enhancement (C.U.R.E.), U01 (NS106845) and R21 Grant. Adeline Vanderver Eli Lilly, Boehringer Ingelhiem, Gilead, Biogen, Illumina, Takeda, Orchard, Passage Bio, Homology, Myrtelle, Synaptixbio, Sanofi, Sana, Affinia related to work in the leukodystrophies.
(Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)